2-Bromo-5-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridin-4(5H)-one | 1039042-31-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-Bromo-5-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridin-4(5H)-one
• 英文别名: 2-bromo-5-[1-(2-pyrrolidin-1-ylethyl)indazol-5-yl]furo[3,2-c]pyridin-4-one
• CAS: 1039042-31-3
• 化学式: C₂₀H₁₉BrN₄O₂
• 分子量: 427.3
• InChiKey: QVQPEUFZADOKAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Bromo-5-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridin-4(5H)-one 、 4-氯-2-氟苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 二甲基亚砜 为溶剂， 生成 2-(4-chloro-2-fluorophenyl)-5-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridin-4(5H)-one
  参考文献：
  名称：

  5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists

  摘要：

  A new series of 5-(pyridinon-1-yl)indazoles with MCH-1 antagonist activity were synthesized. Potential cardiovascular risk for these compounds was assessed based upon their interaction with the hERG potassium channel in a mini-patch clamp assay. Selected compounds were studied in a 5-day diet-induced obese mouse model to evaluate their potential use as weight loss agents. Structural modification of the 5-(pyridinon-1-yl) indazoles to give 5-(furopyridinon-5-yl) indazoles provided compounds with enhanced pharmacokinetic properties and improved efficacy. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.039
• 作为产物：
  描述：

  5-[1-(2-Pyrrolidin-1-ylethyl)indazol-5-yl]furo[3,2-c]pyridin-4-one 在 pyridinium tribromide 作用下， 以 二氯甲烷 、 溶剂黄146 为溶剂， 以31%的产率得到2-Bromo-5-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-indazol-5-yl)furo[3,2-c]pyridin-4(5H)-one
  参考文献：
  名称：

  5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists

  摘要：

  A new series of 5-(pyridinon-1-yl)indazoles with MCH-1 antagonist activity were synthesized. Potential cardiovascular risk for these compounds was assessed based upon their interaction with the hERG potassium channel in a mini-patch clamp assay. Selected compounds were studied in a 5-day diet-induced obese mouse model to evaluate their potential use as weight loss agents. Structural modification of the 5-(pyridinon-1-yl) indazoles to give 5-(furopyridinon-5-yl) indazoles provided compounds with enhanced pharmacokinetic properties and improved efficacy. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.039

文献信息

• 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES
  申请人：Guzzo Peter Robert

  公开号：US20090318439A1

  公开（公告）日：2009-12-24

  Compounds are disclosed. The compounds act as MCH1 modulators. Other embodiments are also disclosed.

  揭示了化合物。这些化合物作为MCH1调节剂。还揭示了其他实施例。
• 5-furopyridinone substituted indazoles
  申请人：Albany Molecular Research, Inc.

  公开号：US08101632B2

  公开（公告）日：2012-01-24

  Compounds are disclosed. The compounds act as MCH1 modulators. Other embodiments are also disclosed.

  本文披露了化合物。这些化合物作为MCH1调节剂。还披露了其他实施方案。
• US8101632B2
  申请人：——

  公开号：US8101632B2

  公开（公告）日：2012-01-24
• [EN] 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES<br/>[FR] INDAZOLES SUBSTITUÉS PAR LA 5-FLUOROPYRIDINONE
  申请人：AMR TECHNOLOGY INC

  公开号：WO2008086409A1

  公开（公告）日：2008-07-17

  [EN] Compounds are disclosed. The compounds act as MCH1 modulators. Other embodiments are also disclosed.
  [FR] L'invention concerne des composés qui agissent comme des modulateurs du MCH1. D'autres modes de réalisation sont également décrits.
• 5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists
  作者：Matthew D. Surman、Emily E. Freeman、James F. Grabowski、Mark Hadden、Alan J. Henderson、Guowei Jiang、Xiaowu (May) Jiang、Michele Luche、Yuri Khmelnitsky、Steven Vickers、Jean Viggers、Sharon Cheetham、Peter R. Guzzo

  DOI：10.1016/j.bmcl.2010.09.039

  日期：2010.12

  A new series of 5-(pyridinon-1-yl)indazoles with MCH-1 antagonist activity were synthesized. Potential cardiovascular risk for these compounds was assessed based upon their interaction with the hERG potassium channel in a mini-patch clamp assay. Selected compounds were studied in a 5-day diet-induced obese mouse model to evaluate their potential use as weight loss agents. Structural modification of the 5-(pyridinon-1-yl) indazoles to give 5-(furopyridinon-5-yl) indazoles provided compounds with enhanced pharmacokinetic properties and improved efficacy. (C) 2010 Elsevier Ltd. All rights reserved.